Physician profile

Arlene Pak

Obstetrics & Gynecology · Raleigh, NC

NPI 1174866206

$6,902.85

in general payments reported to CMS, 2019-2025

45 companies · $2,117 in 2025

The $2,117 reported for 2025 was more than what 94% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$3,260.71
Travel and Lodging$1,064.34
Education$90.05

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Intuitive Surgical, INC. $1,298.97 2021-2025
Bayer Healthcare Pharmaceuticals INC. $651.44 2019-2025
Mayne Pharma Commercial LLC $541.24 2022-2025
Astellas Pharma US INC $492.04 2022-2025 Veozah, Myrbetriq
Pfizer INC. $482.44 2019-2025
Abbvie INC. $388.96 2019-2025
Evofem Biosciences, INC. $341.36 2020-2025 Phexxi, Solosec, Phexx
Biogen, INC. $248.44 2024-2025 Zurzuvae
Therapeuticsmd, INC. $245.16 2019-2022
Daiichi Sankyo INC. $187.15 2019-2021
Organon LLC $152.90 2022-2025 Nexplanon
Astellas Pharma Global Development $139.54 2023-2025 Veozah
Agile Therapeutics, INC. $135.90 2021-2024 Twirla
Exeltis, USA INC. $132.46 2021-2025 Slynd
Avion Pharmaceuticals $130.30 2019-2022
Show all 45 companies
CompanyGeneral paymentsYearsTop products
Shield Therapeutics INC $125.24 2023-2024 Accrufer
Sage Therapeutics, LLC $91.59 2021-2023
Myriad Women'S Health, INC. $90.12 2023
Channel Medsystems, INC. $89.50 2023
Aspira Women'S Health INC $89.34 2021-2024 Ova1
Amgen INC. $85.78 2019-2024 Evenity, Prolia
Biohaven Pharmaceutical Holding Company LTD. $80.50 2022
Baxter Healthcare $53.77 2021-2022
Ethicon US, LLC $52.97 2019
Amag Pharmaceuticals, INC. $50.54 2019-2020
Coopersurgical, INC. $49.34 2019-2025 Endosee
Hologic Sales and Service, LLC $45.68 2019-2024 Acessa Provu System, Myosure Tissue Removal Device, Novasure
Myovant Sciences INC. $38.31 2022
Novo Nordisk INC $37.29 2024-2025 Wegovy
Sumitomo Pharma America, INC. $35.66 2023-2024 Gemtesa, Myfembree
Medicem INC. $31.52 2020
Exact Sciences Corporation $29.48 2023-2025 Cologuard Collection Kit, The Cologuard Plus Collection Kit
Lupin INC. $28.42 2020-2021
Meditrina $26.19 2019-2022
Biohaven Pharmaceuticals, INC. $24.34 2020
Scynexis, INC. $23.58 2022
Dexcom, INC. $23.53 2025 Dexcom G6 Transmitter
Millicent US INC $22.11 2021
Medtronic, INC. $18.78 2022
Mylan Pharmaceuticals INC. $16.50 2021
Lsi Solutions INC $16.05 2024 Fornisee
Vertical Pharmaceuticals, LLC $15.99 2019
Duchesnay USA Incorporated $14.84 2019
Glaxosmithkline, LLC. $14.82 2020
Gynesonics, INC. $12.77 2023 Sonata Sonography-Guided Transcervical Fibroid Ablation System

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Arlene Pak

$6,902.85

in general payments reported 2019-2025

Years
2019-2025
Top company
Intuitive Surgical, INC.
Context
The $2,117 reported for 2025 was more than what 94% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).

https://glasscript.com/doctor/4212003/arlene-pak

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.